Search

Background Studies have reported an association between serum perfluoroalkyl substances (PFASs) and asthma. However, few studies have examined the possible associations between PFASs and the 16-kDa club cell secretory protein (Clara) (CC16) level, a prominent biomarker of asthma, among adolescents. Methods We recruited a total of 231 asthmatic children and 225 non-asthmatic controls in the Genetic and Biomarkers study for Childhood Asthma (GBCA) in northern Taiwan from 2009 to 2010. Structured questionnaires were administered by face-to-face interview. Urine CC16 was determined by an enzyme-link immunoassay kit. Multiple general linear models were employed to examine the associations between PFASs and urinary CC16 levels. Results Asthmatic participants had significantly higher serum PFAS concentrations overall than the healthy controls. After adjusting for confounding factors, urinary CC16 was significantly, negatively associated with PFASs, especially PFOS, PFOA, PFDA and PFNA, and especially among males, as follows: PFOS (β = −0.003, 95% confidence interval [CI]: −0.004, −0.002), PFOA (β = −0.045, 95% CI: −0.086, −0.004), and PFHxA (β = −0.310, 95% CI: −0.455, −0.165) among asthmatic boys, and PFDA (β = −0.126, 95%CI: −0.241, −0.012) and PFNA (β = −0.329, 95% CI: −0.526, −0.132) among non-asthmatic boys. Among girls, PFDA (β = −0.088, 95% CI: −0.172, −0.004), was the only PFAS significantly associated with CC16. Significant interaction effects (p < 0.15) on CC16 levels were found between asthma and PFOS, PFOA, PFBS and PFHxA in all participants. Conclusion Our overall results showed that serum PFASs were significantly, inversely associated with CC16 levels. Associations were stronger among males. [ABSTRACT FROM AUTHOR]

Previous studies have demonstrated associations between serum levels of perfluoroalkyl substances (PFASs) and asthma or asthma related-biomarkers. However, no studies have reported a possible relationship between PFASs exposure and lung function among children. The objective of the present study is to test the association between PFASs exposure and lung function in children from a high exposure area by using a cross-sectional case-control study, which included 132 asthmatic children and 168 non-asthmatic controls recruited from 2009 to 2010 in the Genetic and Biomarkers study for Childhood Asthma. Structured questionnaires were administered face-to-face. Lung function was measured by spirometry. Linear regression models were used to examine the influence of PFASs on lung function. The results showed that asthmatics in our study had significantly higher serum PFAS concentrations than healthy controls. Logistic regression models showed a positive association between PFASs and asthma, with adjusted odds ratios (ORs) ranging from 0.99 (95% confidence interval [CI]: 0.80–1.21) to 2.76 (95% CI: 1.82–4.17). Linear regression modeling showed serum PFASs levels were significantly negatively associated with three pulmonary function measurements (forced vital capacity: FVC; forced expiratory volume in 1 s: FEV 1 ; forced expiratory flow 25–75%: FEF 25–75 ) among children with asthma, the adjusted coefficients between lung function and PFASs exposure ranged from −0.055 (95%CI: −0.100 to −0.010) for FVC and perfluorooctane sulfonate (PFOS) to −0.223 (95%CI: −0.400 to −0.045) for FEF 25–75 and perfluorooctanoic acid (PFOA). PFASs were not, however, significantly associated with pulmonary function among children without asthma. In conclusion, this study suggests that serum PFASs are associated with decreased lung function among children with asthma. [ABSTRACT FROM AUTHOR]